These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34933097)

  • 21. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
    Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
    Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
    Santos-Ferreira D; Diaz SO; Ferreira JP; Girerd N; Pellicori P; Mariottoni B; Cosmi F; Hazebroek M; Verdonschot JAJ; Cuthbert J; Petutschnigg J; Heymans S; Staessen JA; Pieske B; Edelmann F; Clark AL; Rossignol P; Fontes-Carvalho R; Cleland JGF; Zannad F
    ESC Heart Fail; 2024 Feb; 11(1):209-218. PubMed ID: 37939716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
    Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
    J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
    Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
    JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
    Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
    Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A
    Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
    Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
    J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
    Ferreira JP; Rossignol P; Pizard A; Machu JL; Collier T; Girerd N; Huby AC; Gonzalez A; Diez J; López B; Sattar N; Cleland JG; Sever PS; Zannad F
    Heart; 2019 Feb; 105(4):307-314. PubMed ID: 30121630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paying Homage to the Power of Proteomics: Insights Into Obesity and Heart Failure From the HOMAGE Trial.
    Harrington J; Tseliou E; Shah S; Shah KS
    J Card Fail; 2022 May; 28(5):787-788. PubMed ID: 35304349
    [No Abstract]   [Full Text] [Related]  

  • 35. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
    Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
    Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance.
    Wada T; Ishikawa A; Watanabe E; Nakamura Y; Aruga Y; Hasegawa H; Onogi Y; Honda H; Nagai Y; Takatsu K; Ishii Y; Sasahara M; Koya D; Tsuneki H; Sasaoka T
    J Endocrinol; 2017 Dec; 235(3):179-191. PubMed ID: 28855315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
    Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
    Trials; 2013 Apr; 14():91. PubMed ID: 23547564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone for heart failure with preserved ejection fraction.
    Pitt B; Pfeffer MA; Assmann SF; Boineau R; Anand IS; Claggett B; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Harty B; Heitner JF; Kenwood CT; Lewis EF; O'Meara E; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; Yang S; McKinlay SM;
    N Engl J Med; 2014 Apr; 370(15):1383-92. PubMed ID: 24716680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.